Bifogade filer
AlzeCure presents new data on its preventive treatment Alzstatin at the Alzheimer's conference AD/PD 2023
Martin Jönsson CEO And Johan Sandin CSO AlzeCure Pharma
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's presentation at the Alzheimer's conference AD/PD 2023 is now available in its entirety on the company's website. The presentation contains new preclinical data with the drug candidate Alzstatin AC-0027875, which is being developed as a preventive and disease-modifying treatment of Alzheimer’s disease.
“I am so happy that AlzeCure is pursuing a gamma-secretase modulator (GSM) project. There is so much genetic and biochemical data supporting this approach, which could be a true primary prevention drug against Alzheimer’s”, said Henrik Zetterberg, co-author and Professor at Sahlgrenska Institute, Gothenburg, Sweden.
The abstract, titled In vitro and in vivo profile of AC-0027875 (ACD680), a novel gamma-secretase modulator for the prevention and treatment of Alzheimer’s disease, was presented Dr. Johan Sandin, CSO at AlzeCure and co-author, and includes new pre-clinical data with ACD680, the recently selected drug candidate in AlzeCure's research platform Alzstatin®.
The presentation includes new preclinical results with AC-0027875, AlzeCure's potent small molecule GSM. The candidate drug reduces the production of toxic Aβ42, which creates harmful plaques in the brain, both in human cell systems and in vivo models, where it can reduce levels by over 50%.
The substance also shows a very high concentration in the brain, which is a big advantage for these small molecule drugs that can more easily cross the blood-brain barrier. GSM represent a promising class of Aβ42-lowering anti-amyloidogenic agents for the treatment of Alzheimer's disease and exhibit several key properties that make them suitable as both a preventive or disease-modifying treatment of the disease.
“AC-0027875 greatly reduces the amount of harmful Aβ42 in our models, and a gamma-secretase modulator such as this is particularly well suited for early, preventive treatment”, said Johan Sandin, CSO at AlzeCure Pharma.
"With the progress we have made in Alzstatin with our new molecule and the increased interest in the field, I am positive about the continued development work and out-licensing discussions as we see the opportunity to both complement potential antibody therapy, but also to potentially prevent patients from developing Alzheimer's", said Martin Jönsson, CEO of AlzeCure Pharma.
The other co-authors of the abstract are Dr. Märta Dahlström, Dr. Maria Backlund, Veronica Lidell, Azita Rasti, Sanja Juric, Dr. Magnus Halldin, Director of Discovery DMPK & Safety assessment, Dr. Pontus Forsell, Head of Discovery & Research på AlzeCure and Dr. Gunnar Nordvall, Director of Medicinal Chemistry på AlzeCure.
The abstract and the presentation are available on AlzeCure's website (https://www.alzecurepharma.se/en/presentations-and-interviews/).